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Huntington’s disease (HD) is an autosomal dominant inherited disorder leading to the loss
inter alia of DARPP-32 positive medium spiny projection neurons (“MSNs”) in the striatum.
There is no known cure for HD but the relative specificity of cell loss early in the disease
has made cell replacement by neural transplantation an attractive therapeutic possibility.
Transplantation of human fetal striatal precursor cells has shown “proof-of-principle” in
clinical trials; however, the practical and ethical difficulties associated with sourcing fetal
tissues have stimulated the need to identify alternative source(s) of donor cells that are
more readily available and more suitable for standardization. We now have available the first
generation of protocols to generate DARPP-32 positive MSN-like neurons from pluripotent
stem cells and these have been successfully grafted into animal models of HD. However,
whether these grafts can provide stable functional recovery to the level that can regularly
be achieved with primary fetal striatal grafts remains to be demonstrated. Of particular
concern, primary fetal striatal grafts are not homogenous; they contain not only the MSN
subpopulation of striatal projection neurons but also include all the different cell types that
make up the mature striatum, such as the multiple populations of striatal interneurons and
striatal glia, and which certainly contribute to normal striatal function. By contrast, present
protocols for pluripotent stem cell differentiation are almost entirely targeted at specifying
just neurons of an MSN lineage. So far, evidence for the functionality and integration of
stem-cell derived grafts is correspondingly limited. Indeed, consideration of the features
of full striatal reconstruction that is achieved with primary fetal striatal grafts suggests
that optimal success of the next generations of stem cell-derived replacement therapy in
HD will require that graft protocols be developed to allow inclusion of multiple striatal cell
types, such as interneurons and/or glia. Almost certainly, therefore, more sophisticated
differentiation protocols will be necessary, over and above replacement of a specific
population of MSNs. A rational solution to this technical challenge requires that we re-
address the underlying question—what constitutes a functional striatal graft?
Keywords: neuronal transplantation, pluripotent stem cell grafts, embryonic stem cells, iPS cells, striatal grafts,
striatal fate, medium spiny neurons, Huntington’s disease
INTRODUCTION
In humans, the adult striatum is composed of two histologically
equivalent nuclei—the caudate nucleus and the putamen—which
together, with other core nuclei in the depths of the forebrain,
make up the basal ganglia (Jain et al., 2001). The striatum
is connected through independent and parallel pathways with
widespread areas of the neocortex, the pallidum, the thalamus
and the brainstem and plays a vital role in the co-ordination
of movement (primary motor control), emotions, and cogni-
tion (Jain et al., 2001). In Huntington’s disease (HD), a genetic
mutation in the huntingtin (htt) gene results in early loss of the
medium sized striatal projection neurons (MSNs) of the striatum,
atrophy of striatal volume (Vonsattel et al., 1985), and disruption
of functional communication through the basal ganglia pathways,
leading to motor, cognitive and psychiatric decline.
Currently, there is no known cure for HD. However, the
specificity of cell loss seen at least in early stages of the disease—
principally involving loss of the MSN projection neurons—has
made cell transplantation a viable therapeutic prospect (Dunnett
and Rosser, 2014). Transplants using primary human fetal striatal
tissue have demonstrated “proof-of-principle” that cell replace-
ment is feasible, that the grafts are safe and do not accelerate
disease progression (Rosser et al., 2002), and importantly have
significant, although incomplete, functional recovery in at least
some patients (Bachoud-Lévi et al., 2000, 2006; Barker et al.,
2013). However, due to the ethical issues associated with the use
of human fetal cells (PFCs) obtained from elective termination of
pregnancies, the logistical issues arising from the amount of fetal
tissue required per patient, and the difficulties in achieving an
appropriate level of standardization and quality control for tissues
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derived from such a recurrent clinical source, better renewable
sources of cells for transplantation are under active exploration.
Human pluripotent stem cells (hPSCs) are the leading contender
under consideration, by virtue of their capacity for indefinite
expansion as well as their potential for differentiation to essen-
tially any mature fate; the principle sources being embryonic
stem cells (ESCs) and/or induced pluripotent stem cells (iPSCs),
followed by directed differentiation in vitro towards a specific
neural phenotype (or phenotypes) prior to transplantation as
required for each disease target.
Over the last 5 years there has been some considerable success
in producing MSN-like neurons from PSC sources, including
from hESCs that have been directed to a neuronal phenotype,
and then ventralised using sonic hedgehog or its agonist, pur-
morphamine (El-Akabawy et al., 2011). To date a small number
of published protocols have also reported differentiation of MSN-
like cells in vitro and post transplantation in the rodent brain, with
limited evidence that the cells could integrate into the host neural
circuitry and receive dopaminergic inputs from the midbrain
and glutamatergic inputs from the cortex while projecting fibers
to the substantia nigra (Aubry et al., 2008; Ma et al., 2012;
Delli Carri et al., 2013; Arber et al., in press). These protocols
and key findings are summarized in Table 1. However, although
there is some evidence that the transplanted cells corrected
motor deficits in a rodent model of striatal neurodegeneration,
in no case to date have the cells demonstrated a full repertoire
of functional improvements that would reliably indicate that
they are indeed authentic MSNs. Thus, we must ask whether
generating neurons with the principal characteristic marker of
the MSN phenotype, viz. that they express the dopamine and
cyclic AMP-regulated neuronal phosphoprotein, DARPP-32, is a
sufficient (or indeed necessary) condition for optimizing func-
tional recovery. Are other features of the intact striatum or other
neuronal subtypes equally important for an optimal, functional
graft?
In order to address this question, it is instructive to revisit first
the separate issue of what have we learned about the composi-
tion and organization provided by experimental grafts of “stri-
atal” PFCs derived from the embryonic ganglionic eminence, for
which we have considerable evidence of robust and reproducible
functional recovery in both rodent and primate animal models.
A rich background literature on the structural, neurochemical,
morphological, connections, electrophysiology and behavioral
reconstruction provided by PFC grafts, and their correspondence
to normal striatum, is summarized in Table 2. Striatal PFC grafts,
whether derived from human, primate or rat embryos, do not
exclusively contain MSNs; they contain cells from the entire
developing striatum (Bachoud-Lévi et al., 2000, 2006; Rosser
et al., 2002; Barker et al., 2013) and have shown more convincing
functional recovery and integration than so far seen from PSC-
derived grafts, strongly suggesting that inclusion of other cell
types of the intact striatum, such as interneurons, should be
considered. This review will therefore attempt to give an overview
of what we have learnt about repairing the intact striatum using
PFC-derived cells (Table 2), and the implications for devel-
oping alternative PSC-based protocols for cell transplantation
in HD.
NORMAL STRIATAL DEVELOPMENT
The mammalian striatum develops within the ventral telen-
cephalon; specifically from the whole ganglionic eminence
(WGE), which can be further subdivided into the lateral, medial
and caudal segments (LGE, MGE and CGE, respectively). Stri-
atal projection neurons originate predominantly in the LGE
whereas striatal interneurons are born primarily in the MGE
(Evans et al., 2012). During striatal development, subsets of
marker genes (transcription factors, etc.) can be used to dif-
ferentiate between different neuronal types, and between differ-
ent stages of development. Consequently, the characterization
of the expression of key genes during normal striatal develop-
ment has become an essential guide for developing and vali-
dating protocols for ex vivo differentiation of PSCs to similar
fates.
For rat and mouse PFC allografts, it has been determined
empirically that the optimal stage of fetal development for tissue
donation coincides with the peak of neurogenesis of the relevant
target population, i.e., around embryonic day E14-15 for striatal
grafts (Dunnett and Björklund, 2000). By contrast, the donor age
for human or primate xenograft or allograft studies is typically
determined by selecting embryos at the equivalent Carnegie stage
known to be effective from rodent studies, i.e., 7–8 weeks of
gestation (9–10 weeks post last menstruation; 17–28 mm crown-
rump length) for human striatal tissue (Butler and Juurlink,
1987; O’Rahilly and Müller, 1987; Dunnett and Björklund, 2000).
There is as yet insufficient data from different clinical studies,
with inadequate information on either donor age or functional
outcomes, to establish the validity of this essentially empirical
principle, not least because of the multiplicity of other factors
that also contribute to graft viability and function (Freeman et al.,
2011).
Within the adult striatum, neurons are heterogeneous and can
be subdivided according to size, density of spines, and utility
of neurotransmitters and neuropeptides. Striatal MSNs consti-
tute 90–95% of all striatal neurons in rodents (and about 80–
85% primates) and are the main output projection neurons of
the striatum (Gerfen, 1992). The MSNs utilize the inhibitory
gamma-amino butyric acid (GABA) as their principle neuro-
transmitter (Gerfen, 1992; Feng et al., 2014) and subpopula-
tions also use enkephalin, dynorphin and/or substance P as
co-transmitters (see Table 2). They also stain for DARPP-32
which, as mentioned earlier provides a commonly-used and
convenient marker of the MSN cell population. The remaining
neurons are spiny and aspiny interneurons (5–10% rodents and
up to 20% in primates) which are classically subdivided into 4
types: parvalbumin-positive, calretinin-positive, neuropeptide Y,
somatostatin and neuronal nitric oxide synthase (NPY/SS/nNOS)
positive, all of which are GABAergic and of medium size, and
the giant aspiny cholinergic (choline acetyltransferase, ChAT-
positive) interneurons ((Freeman et al., 1995; Durieux et al.,
2011; Feng et al., 2014), see Table 2). The functional contribution
of these interneuronal subpopulations to striatal processing is
not well characterized, although there has been an increase in
research in this area recently (Tepper et al., 2010). It is clear, how-
ever, that the striatal MSNs do not simply relay untransformed
information from cortex to globus pallidus, but information
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Table 1 | Studies of grafts of PSCs into rodent striatum.
Protocol Cell source Host treatment Transplant Brief summary of results
Dinsmore et al.
(1996)
mESC (E14TG2a; D3) QA lesioned
rat striatum
Daily cyclosporine
100,000–1,000,000
cells.
Survival up to 6 wk
Treatment of pluripotent ES cell cultures with retinoic
acid (RA) induced populations of GABAergic express-
ing neurons (no specific neuronal type was targeted).
Grafts containing 100,000 cells produced biggest
grafts. Grafts stained positively for AChE, Thy1.2, TUJ1,
NSE and GABA. No neurite outgrowth was determined
due to the absence of a species specific marker.
Kallur et al. (2006) NSCs from primary
striatal tissue
expanded in vitro as
neurospheres
Intact striatum of
neonatal rat
(2–3 days) No
immune
suppression
100,000 cells
Survival 4 and 16 wk
At 4 months 6–10% of cells had survived, the majority
were located in the striatum but some had migrated
to the GP, cortex or corpus callosum. At 4 months,
the number of NESTIN positive cells had decreased
whereas the number of DCX and NEUN cells had
increased compared to at 1 month. Some cells were
GFAP positive and the majority of all neurons stained
positively for parvalbumin. A selection of neurons
had morphology characteristic of mature neurons with
long branching processes and visible dendritic spines
whereas others had more astrocyte/oligodendrocyte
like morphology.
Joannides et al.
(2007a)
H9; HUES9 QA lesioned
rat striatum
Daily cyclosporine
100,000–250,000
cells
Survival at 6 wk
Cells grown under optimized and fully defined human
neuralizing medium under substrate-free conditions.
No tumors evident following transplantation. Dou-
blecortin (DCX) and NeuN positive neurons identified.
Limited GFAP staining also evident- suggestive of
some astrocyte differentiation. No DARPP-32 present,
no sign of neuron migration from graft core.
Song et al. (2007) Miz-hESC1 QA lesioned
rat striatum
Daily cyclosporine
20,000 cells
Survival at 3 wk
Some cells migrated to the cortex and formed “aggre-
gates” that were Nestin positive/NeuN negative.
Some cells were GFAP positive. Cells remaining in the
striatum migrated to the lesion core and were DCX and
GAD67 positive/DARPP-32 negative. Improved apo-
morphine rotations at 1, 2 and 3 weeks compared to
sham group. No overgrowth reported.
Aubry et al. (2008) SA-01 (H9) QA lesioned
striatum in
nude rat
No immune
suppression
50,000–200,000 cells
Survival 4–6 wk
Grafts from “early” stage cells (day 21–30 of the
protocol) showed no DARPP-32 expressing cells and
developed “teratoma-like regions” whilst cells grafted
from the “later” stage (day 46–59) of the protocol
showed clusters of DARPP-32 (21% of NeuN positive
neurons)/AChE negative cells and contained P-zones.
The cells had medium sized bodies (10–16 µm), were
bi-polar and showed extensive neurite outgrowth.
There was overgrowth 13–15 weeks after the graft. No
functional assessment.
Lee et al. (2009) Adipose-derived
stem cells (ASCs)
QA lesioned
rat striatum
Daily cyclosporine
100,000 cells Grafts reduced apomorphine-induced rotations (1–4
weeks after), lesion volume, and striatal apoptosis.
60 day old
R6/2 mouse
Daily cyclosporine
500,000 cells Grafts improved
rotarod performance and limb clasping,
increased survival,
attenuated the loss
of striatal neurons,
and reduced the
Htt+ aggregates.
Cells expressed DCX, TUJ1 and GAD.
(Continued)
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Table 1 | Continued
Protocol Cell source Host treatment Transplant Brief summary of results
Nasonkin et al.
(2009)
hESCs (BG01) Unlesioned Striatum
in nude rats
No immune
suppression
15,000 cells
Survival 1.5, 3
and 6 mo.
Following transplantation nestin and DCX expression
decreased and TUJ1 increased. DARPP-32, calretinin
and parvalbumin expression at 6 months, no GAD67.
Synaptophysin evident and sparse Glur2/3. Axonal pro-
jections to the GPe and sub thalamic nucleus seen. No
overgrowth, no functional assessment.
Vazey et al. (2010) ENVY
(GFP-expressing)
QA lesioned
rat striatum
Daily cyclosporine
75,000 cells
Survival 4 and 8 wk
Grafted cells expressed MAP2 and NeuN at both time
points, no DARPP-32 or GAD67. Overgrowth seen in 1
graft at 8 weeks. No functional assessment.
Ma et al. (2012) hESCs QA lesioned striatum
in SCID mice
No immune
suppression
100,000 cells
Survival 16 wk
Shorter protocol than previous attempts to generate
LGE neural precursors that predominately differenti-
ated into DARPP-32-expressing neurons. Cells were
grafted after 40 days in vitro and 4 months after
transplantation showed no over-growth and were pos-
itive for DARPP-32, MEIS2, CTIP2, enkephalin and
substance P. Cells were multipolar, branched and had
numerous dendritic buttons revealed through synap-
tophysin staining. Small populations of the neurons
also expressed ChAT, vGLUT1, 5-HT, TH and cal-
bindin. Functional recovery was seen on the rotarod
and through an increase in stride length which was
attributed to the host cortical and nigral inputs to the
grafts as well as the projections afforded to the SN
from the grafts.
El-Akabawy et al.
(2012)
cmyc-ERTAM hNSC
(STROC05)
R6/2 HD mouse
No immune
suppression
75,000 cells
Survival up to 6 wk
Tested on a battery of behavior tests including rotarod,
Cells did not diminish disease progression, possibly
due to the short life span of the mouse (16 weeks).
There was no DARPP-32. There was no sign of graft
rejection but this does not rule out an early immune
response on the graft.
Delli Carri et al.
(2013)
hESCs (H9 and
HS401)
QA lesioned rat
striatum Daily
cyclosporine
500,00 cells
Survival at 3, 6 and 9
wk
Used the same concentration of SHH as Ma et al.,
to induce a ventral telencephalic identity and charac-
terized extensively to ensure LGE precursors. Cells
grafted at Day 38 of the protocol. At 6 and 9 weeks
MAP2ab mad TUJ1 positive neurons were seen. At 9
weeks post-transplant FOXP1, FOXP2 and DARPP-32
staining was found in the grafts but not quantified. Pro-
jection of Nestin fibers into the intact striatum showed
integration between host and graft. Amphetamine-
induced rotations were compared before and after
grafting from 3 weeks and results hinted at functional
recovery, however animal numbers were too low to
suggest a significant behavioral effect.
Nicoleau et al.
(2013)
hESCs (H9) QA lesioned striatum
of nude rats.
No immune
suppression
100,000 cells
Survival at 5 mo.
Optimized concentration of SHH and WNT signaling
to produce human ventral telencephalic precursors
that were characterized extensively before grating. Day
25 differentiated hESC grafted, DARPP-32 and FOXP1
found in grafts, as yet no behavioral assessment has
been carried out.
Arber et al. (in
press)
hESCs (H7) Activin
protocol
QA lesioned rat
striatum Daily
cyclosporine
500,000 cells
Survival at 4–16 wk.
DARPP-32 shown in grafts at 16 weeks containing
CTIP2, FOXP2 and calbindin positive neurons. No over-
growth.
throughout is modulated in the course of the striatal contribution
to action selection, motor learning and habit formation. Thus,
it is highly likely that the striatal cholinergic and GABAergic
interneurons play key roles in effecting these functional processes
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Table 2 | Molecular, Anatomical and Functional features of intact striatum, primary fetal striatal grafts, and pluripotent stem cell-derived
grafts †.
Striatal grafts (selected refs) Notes∗ PSC grafts (all refs ††)
Cell morphology (Golgi):
MSN : 90–95% medium sized
spiny projection
Roberts and DiFiglia (1988), Wictorin
et al. (1989), Helm et al. (1990),
Clarke et al. (1994), Olsson et al.
(1995)
+ [in P zones] ?
SIN : 4–8% medium sized spiny
and non-spiny
Roberts and DiFiglia (1988), Helm
et al. (1990), Clarke et al. (1994)
+ [in P zones] ?
GCN : 1–2% giant aspiny neurons Helm et al. (1990, 1992) + [in P zones] ?
Astrocytes : structural and
reactive
Petit et al. (2002), Zhu et al. (2013) + [patchy] + Kallur et al. (2006), Joannides
et al. (2007b), Song et al. (2007)
Oligodendrocytes : myelinating
internal capsule
? ?
[Microglia : in response to
damage or inflammation]
Freeman et al. (2000) – [throughout] ?
[pallidal-like, medium, aspiny] Graybiel et al. (1989), Clarke et al.
(1994)
+ [in NP zones] ?
[cortical-like, pyramidal—in NP
zones]
Clarke et al. (1994) + [in NP zones] ?
Neurotransmitters:
MSN and SIN: GABA, GAD Isacson et al. (1985), Roberts and
DiFiglia (1988), Clarke and Dunnett
(1993), Piña et al. (1994b)
+ −Nasonkin et al. (2009), Vazey
et al. (2010)
+ Dinsmore et al. (1996), Lee
et al. (2006), Song et al. (2007),
Arber et al. (in press)
MSN: Enk, proenkephalin Roberts and DiFiglia (1988), Graybiel
et al. (1989), Sirinathsinghji et al.
(1990), Emerich et al. (1991), Camp-
bell and Björklund (1995), Freeman
et al. (2000)
+ [in P zones] Ma et al. (2012)
MSN: Dyn, prodynorphin Sirinathsinghji et al. (1990) + ?
MSN: SP, preprotachykinin Sirinathsinghji et al. (1990), Helm
et al. (1992), Campbell and Björklund
(1995), Freeman et al. (2000)
+ [in P zones] Ma et al. (2012)
SIN: parvalbumin, PV Capetian et al. (2009) + + Saporta et al. (2001), Kallur
et al. (2006), Nasonkin et al.
(2009)
SIN: calretinin, CR Freeman et al. (2000), Keene et al.
(2007), Capetian et al. (2009)
+ [in P zones] + Saporta et al. (2001), Kallur
et al. (2006), Nasonkin et al.
(2009), El-Akabawy et al. (2011)
SIN: neuropeptide Y, preproNPY Morris et al. (1989), Sirinathsinghji
et al. (1990)
+ [in P zones] ?
SIN: somatostatin, SOM Graybiel et al. (1989), Morris et al.
(1989), Freeman et al. (2000),
Capetian et al. (2009)
+ [in P zones] ?
SIN: nitric oxide synthase, NOS ? ?
GCN: Acetylcholine, ChAT, AChE Graybiel et al. (1989), Helm et al.
(1992), Freeman et al. (2000)
+ [in P zones] + Dinsmore et al. (1996), Ma
et al. (2012)
calbindin, calbindin D28k Graybiel et al. (1989), Freeman et al.
(2000)
+ [P and NP zones] + Saporta et al. (2001), El-
Akabawy et al. (2011), Ma et al.
(2012), Arber et al. (in press)
Molecular markers
Pluripotent cell markers (Sox1 etc) ? ?
Neuronal precursors (TUJ1,
Nestin, NSE, DCx etc)
? + Dinsmore et al. (1996), Kallur
et al. (2006), Lee et al. (2006),
Joannides et al. (2007b), Song
et al. (2007), Nasonkin et al.
(2009), Delli Carri et al. (2013)
(Continued)
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Table 2 | Continued
Striatal grafts (selected refs) Notes∗ PSC grafts (all refs ††)
zones of tumor/teratoma
overgrowth
+/– + Song et al. (2007), Aubry et al.
(2008), Vazey et al. (2010)
MSNs: DARPP-32 Wictorin et al. (1989), Labandeira-
García et al. (1991), Campbell and
Björklund (1995), Freeman et al.
(2000), Keene et al. (2007)
+ [in P zones] –Vazey et al. (2010), El-Akabawy
et al. (2012)
+ (Kallur et al. (2006), Nasonkin
et al. (2009), El-Akabawy et al.
(2011), Ma et al. (2012), Delli
Carri et al. (2013), Nicoleau et al.
(2013), Arber et al. (in press)
MSNs: FoxP1, FoxP2, Ctip2 +/? + Ma et al. (2012), Delli Carri
et al. (2013), Nicoleau et al.
(2013), Arber et al. (in press)
SINs: NADPH diaphorase Roberts and DiFiglia (1988), Emerich
et al. (1991), Pundt et al. (1996)
+ ?
SINs: NKX2.1, ? + Aubry et al. (2008), El-
Akabawy et al. (2011)
SINs: Mash1, ? + El-Akabawy et al. (2011)
SINs: Dlx1, Dlx2 ? + El-Akabawy et al. (2011)
VMAT1 ? + Kallur et al. (2006)
Striatal enriched phosphoprotein,
STEP
Fricker et al. (1994) + [in P zones]
Efferent projections
Direct pathway : MSNs > GPi Wictorin et al. (1990b) + ?
Direct pathway : MSNs > SNr Wictorin et al. (1989, 1990b) + Ma et al. (2012)
Indirect pathway : MSNs > GPe Wictorin et al. (1989, 1990b), Clarke
and Dunnett (1993), Olsson et al.
(1995)
+ [from P zones] Nasonkin et al. (2009)
[outgrowth into neocortex] Wictorin et al. (1990a) + [aberrant]
Afferent projections
Neocortex layer III and V,
glutamate, topographic
Pritzel et al. (1986), Wictorin and
Björklund (1989), Wictorin et al.
(1989)
+ [P and NP zones] Ma et al. (2012)
Substantia nigra compacta,
dopamine (CCK-)
Pritzel et al. (1986), Clarke et al.
(1988), Wictorin et al. (1989),
Labandeira-García et al. (1991),
Clarke and Dunnett (1993), Capetian
et al. (2009)
+ [into P zones] Ma et al. (2012), Arber et al. (in
press)
Raphé nucleus, serotonin Wictorin et al. (1988), Labandeira-
García et al. (1991), Pierret et al.
(1998), Petit et al. (2002)
+ ?
Thalamus, VA, VL . . ., glutamate (?) Pritzel et al. (1986), Wictorin et al.
(1988)
+ ?
Electrophysiology
in vitro membrane properties Walsh et al. (1988), Siviy et al. (1993) + [normal or aberrant] ?
Local connections > EPSPs Walsh et al. (1988) + [EPSPs + IPSPs] ?
Patch-clamp features of inward
rectifying current
Surmeier et al. (1992) + [relatively normal] ?
responses to pharmacological
challenges
Nakao et al. (2000), Chen et al.
(2002)
+ ?
Monosynaptic EPSPs
cortex > MSN
Rutherford et al. (1987), Walsh et al.
(1988), Xu et al. (1991)
+ [aberrant] ?
Monosynaptic EPSPs nigra > MSN ? ?
Monosynaptic EPSPs
thalamus > MSN
Xu et al. (1991) + [aberrant] ?
Monosynaptic IPSPs : MSN > GPe ? ?
Monosynaptic IPSPs : MSN > GPi Nakao et al. (1999) + ?
Monosynaptic IPSPs : MSN > SNr + [aberrant] ?
LTP and LTD plasticity at
corticostriatal synapse
Mazzocchi-Jones et al. (2009, 2011) + ?
Fast spiking interneurons ? ?
(Continued)
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Table 2 | Continued
Striatal grafts (selected refs) Notes∗ PSC grafts (all refs ††)
Receptors
dopamine D1, D2 receptors Isacson et al. (1987), Deckel et al.
(1988b), Liu et al. (1990), Lu and
Norman (1993)
+ ?
glutamate NMDA receptors Siviy et al. (1993), Hussain et al.
(2004)
+ ± Nasonkin et al. (2009)
GABA receptors ? ?
ACh muscarinic receptors Isacson et al. (1987), Deckel et al.
(1988a), Liu et al. (1990), Lu and
Norman (1993)
+ ?
µ-Opiate receptors Isacson et al. (1987), Lu and Norman
(1993)
+ [in P zones] ?
cannabinoid CB1 and CB2 ? ?
receptors
adenosine receptors ? ?
CCK receptors Lu and Norman (1993) + ?
Neurochemistry
Striatal derived GABA release in
striatum or GP
Sirinathsinghji et al. (1988), Camp-
bell et al. (1993)
+ ?
Striatal CCK regulation of Sirinathsinghji et al. (1993) + ?
DA release
Functional recovery
Motor—activity and locomotion Isacson et al. (1984), Deckel et al.
(1986)
+ Ma et al. (2012)
Motor asymmetry, rotation Dunnett et al. (1988), Norman et al.
(1988, 1989)
+ +Song et al. (2007), Delli Carri
et al. (2013)
Motor coordination and balance
(e.g., rotarod)
Giordano et al. (1990) + –El-Akabawy et al. (2012) + Lee
et al. (2006), Ma et al. (2012)
Motor skills—e.g., paw reaching Dunnett et al. (1988), Montoya
et al. (1990), Döbrössy and Dunnett
(2001), Klein et al. (2013)
+ ?
Sensorimotor, e.g., neglect Deckel et al. (1986) + ?
Motor learning Mayer et al. (1992), Döbrössy and
Dunnett (1998), Brasted et al. (1999)
+ ?
Cognition—classic prefrontal
tasks, e.g., delayed alternation
Deckel et al. (1986), Dunnett and
White (2006)
+ ?
Cognition—simple learning tasks,
e.g., passive avoidance
Piña et al. (1994a), Giordano et al.
(1998)
+ ?
Cognition—S-R vs. incentive based
learning
? ?
Cognition—executive function,
e.g., set shifting
? ?
Psychiatric—impulsivity and Reading and Dunnett (1995) + ?
disinhibition
Psychiatric—sensitivity to reward ? ?
and motivation
†This table provides a summary of the range of morphological, neurotransmitter, receptor, molecular, cellular, functional features of the normal striatum against which
primary fetal and stem cell derived grafts have been evaluated. Comprehensive review is beyond the scope of the present application; see individual references for
details.
††See Table 1 for full description.
Abbreviations: CCK, cholecystokinin; CR, calretinin; Dyn, dynorphin; Enk, enkephalin; GABA, gamma-amino butyric acid; GCN, giant cholinergic interneurons; GPe,
external segment of globus pallidus; GPi, internal segment of globus pallidus; LTD, long-term depression; LTP, long-term potentiation; MSN, striatal medium spiny
projection neurons; NOS, nitric oxide synthase; NPY, neuropeptide Y; PSC, pluripotent stem cell; PV, parvalbumin; SIN, striatal interneuron; SNc, substantia nigra
pars compacta; SNr, substantia nigra pars reticulata; SOM, somatostatin; SP, substance P; VA, ventral anterior nucleus ; VL, ventrolateral nucleus.
∗Notes. + Present. – Absent, ? no known published data.
(Do et al., 2012). To take just one example, Calabresi and col-
leagues show that the nitric oxide and cholinergic interneurons
exert feed-forward control of the excitability of the MSNs to
coordinate alternative forms of neuroplasticity during motor
learning (Centonze et al., 1999). In addition, aberrant GABAer-
gic cortical interneuron development is associated with some
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neuropsychological disorders such as schizophrenia (Arber et al.,
in press).
A further level of organization is important for normal striatal
function: the parallel direct and indirect pathways for down-
stream information transfer. One subpopulation of striatal MSNs
projects directly to their principle downstream targets via the
internal segment of the globus pallidus and substantia nigra
pars reticulata, and thence to thalamus and brainstem. A second
subpopulation projects to the external segment of the globus
pallidus which interacts reciprocally with subthalamic nucleus
prior to then converging via this indirect route, on the same
downstream targets. Whereas the striatal matrix contributes to
both direct and indirect pathway projections, there is growing
evidence that the striosomes contribute to the direct pathway
only (Fujiyama et al., 2011). Moreover, the direct and indi-
rect pathways differ in their co-transmitters which they operate
with GABA (substance P and dynorphin vs. enkephalin, respec-
tively (Gerfen and Young, 1988; Albin et al., 1989)), and in
the subtypes of dopamine receptors to which they differentially
respond (excitatory D1 vs. inhibitory D2 receptors respectively
(Gerfen and Young, 1988; Jimhénez-Castellanos and Graybiel,
1989; Gerfen et al., 1990)). The importance of this organization
to striatal repair lies in the highly influential model introduced
by DeLong (1990), based on initial distinctions introduced by
Albin et al. (1989), which suggests that different hyperkinetic
vs. hypokinetic motor disorders can be characterized in terms
of imbalances between direct and indirect pathways outputs.
Thus, so-called “hyperkinetic” conditions including HD result
from excess activation of the indirect pathways, as evidenced
for example by preferential loss of enkephalinergic over sub-
stance P MSNs in a post mortem HD brain (Reiner et al.,
1988), and which may be corrected symptomatically by D2
down-regulation. The task for any reparative therapy—whether
based on cell replacement or some other method of inducing
intrinsic reorganization and plasticity—is to restore the balance
between counterbalanced net excitatory and inhibitory pathways
and their connections, not simply restoring striatal input-output
relays. The organization of the neostriatum in health and dis-
ease is fundamental to its normal function and dysfunction,
and sets precise challenges of how to restore a sufficient match
to the healthy organization if any reparative therapy is to be
effective.
STRIATAL GRAFTING
The most widely used models for studies of striatal repair
and transplantation have been excitotoxic lesions of the stria-
tum in rats and primates. Although transgenic models have
recently become more widely available, the cellular pathology is
substantially more widespread throughout the brain and body
than seen in the human condition (Morton et al., 2000). As a
consequence, notwithstanding their utility for developing other
strategies for neuroprotection, genetic mutation models have
proved to be less suitable for studying cell-based repair of focal
striatal degeneration (Dunnett et al., 1998) than the classi-
cal approach using excitotoxins. Of these, the quinolinic acid
(QA) lesion model of HD is the preferred contemporary option
(Beal et al., 1986), as it depletes the MSNs relatively selectively
and without the additional side effects of earlier alternatives,
such as kainic or ibotenic acids. Recently, in addition to induc-
ing MSN cell death, it has also been shown that QA causes a
decrease in the number of parvalbumin and NPY interneurons,
sparing calbindin and ChAT positive interneurons, similar to
the selective profile of cell loss in human HD (Feng et al.,
2014).
Striatal transplantation is a relatively straightforward proce-
dure involving injection of striatal primordium, typically derived
from the developing fetal forebrain and prepared as a dissociated
cell suspension, directly into the host striatum under stereotactic
guidance (Schmidt et al., 1981; Isacson et al., 1984). Similar
protocols have been widely used in many labs worldwide and
found to be relatively simple, reliable and reproducible, and rat
allograft studies dominate the striatal-grafting field. Such experi-
ments have allowed us to understand what constitutes an optimal
striatal graft, not only in terms of cell survival, differentiation and
anatomical integration, but also in terms of functional impact
on the host brain and host behavior (Dunnett et al., 2000) (see
Table 2).
Striatal mouse allograft experiments also exist but as yet
have not been as forthcoming due to inconsistencies in the
long term survival of grafts in the mouse brain (Roberton
et al., 2013). Furthermore, human-rat xenograft experiments
have served not only as a precursor to clinical trials of cell
transplantation in man, but also as an important model to
study normal human fetal development and cell fate. Striatal
allografts in primates have been used both for scaling up pro-
tocols and to demonstrate similar profiles of functional motor
and cognitive recovery in the more complex primate basal gan-
glia (Kendall et al., 1998; Palfi et al., 1998), prior to clini-
cal application. Finally we now have in vivo and post mortem
evidence accumulating from human-human allografts in HD
patients that have entered the first generation of clinical tri-
als of PFC transplantation in this disease (Bachoud-Lévi et al.,
2000; Freeman et al., 2000; Rosser et al., 2002; Cicchetti et al.,
2011).
The comparison between within- and cross-species studies
highlights the fact that graft growth and recovery of function
must be considered within the context of species-specific rate
of neuronal development of the donor tissue, which trans-
lates directly into very different timelines for experimental
studies of tissue derived from mice, rats, primates and man,
irrespective of the host. Collectively, PFC transplant studies
have utilized a range of cell preparation methods and have
reported a range of outcome measures including cell mor-
phology, neurotransmitter type, molecular markers, projec-
tions, electrophysiology, and functional recovery; so what have
such experiments highlighted and how should this be applied
to the characterization and evaluation of PSC-derived donor
cells?
CELL MORPHOLOGY
Rat WGE grafted into the QA-lesioned host striatum reveals
a relatively homogenous population of neuronal cell bodies
within the graft as indicated by general histological stains such
as NEUN or cresyl violet. However, from the earliest grafting
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experiments it is clear that different neuronal types develop
within the striatal tissue grafted. For example Golgi experiments
highlighted the presence of at least 5 types of medium sized,
spiny neurons as well as aspiny neurons (Helm et al., 1990),
and non-striatal (e.g., pyramidal) as well as striatal cell types
(Clarke et al., 1994). Early use of neurochemical stains revealed
two morphologically distinct regions, acetylcholinesterase (AChE
positive) “P-zones” (30–40%) and AChE negative non-P (NP)-
zones (Isacson et al., 1987; Graybiel et al., 1989; Wictorin
et al., 1989; Pakzaban et al., 1993), with the latter having at
least three fold less DARPP-32 positive MSNs (Wictorin and
Björklund, 1989; Nakao et al., 1994). In addition to DARPP-32
expression, the P-zones positively stain for striatal interneu-
rons whereas the NP zones are comprised primarily of non-
striatal cell types that also originate from within the ganglionic
eminence primordium, such as pallidal and cortical neurons
(Clarke et al., 1994). These distinctive zones have been shown
in rat (Watts et al., 2000a,c), human (Cisbani et al., 2013)
and to a lesser degree in mouse allografts (Döbrössy et al.,
2011) and human-rat xenografts (Grasbon-Frodl and Brundin,
1997; Grasbon-Frodl et al., 1997; Sanberg et al., 1997), show-
ing that such autonomous patterning is not species-specific.
Although when first observed it was natural to hypothesize that
the grafts were developing an intrinsic striosome-matrix orga-
nization (Isacson et al., 1987), it was quickly realized that this
was not the case. Rather, the ganglionic eminence gives rise to
diverse populations of cortical, pallidal and other deep forebrain
progenitors as well as the target precursors of striatal fate(s).
Thus, the patches of positive staining for AChE co-localized
with a broad range of markers of all striatal types, striosomes
as well as matrix, that aggregated into a patchy organization
(designated “P zones” to distinguish the term from Gerfen’s
“patch” terminology for striosomes) interspersed with a non-P
compartment (or “NP-zones”) comprising neurons of primarily
cortical, pallidal and other non-striatal phenotypes (Graybiel
et al., 1989).
To date PSC-based protocols have not clearly identified a
similar differentiation into different zones within the grafts (see
Table 2). This could suggest a relative purity of the differenti-
ated PSC-derived neurons (e.g., relatively pure yields of striatal
MSNs), with no contamination from cortical and other forebrain
phenotypes, exactly as designed. Alternatively, the grafted PSC-
derived neurons typically show continuing expression of markers
of immaturity, such as nestin and doublecortin, and it may simply
be that the markers necessary to reveal a mature heterogeneity
of organization are not yet expressed at the relatively short sur-
vival times so far studied. Thirdly, the intercellular signals that
guide self-organization and aggregation of striatal-like cells in
PFC grafts may simply not be expressed in PSC-derived neurons
within the grafts. Crucial to interpretation of this first obvious
difference in histological descriptions of PSC-derived vs. PFC-
derived striatal transplants, lies the question whether the distinct
P-zones seen in classical striatal graft studies are even required
(let alone optimal) for a functional graft, or do they only serve
as a way of demonstrating that conventional grafts are intrinsi-
cally suboptimal by virtue of contamination with irrelevant cell
types.
When primary grafts involve a fetal dissection that is restricted
to LGE (the zone within which the bulk of the MSNs origi-
nate), the size of the P-zones increases to 80–90% of the total
graft volume, and the proportion of DARPP-32 expression and
MSN-type neurons within the grafts is correspondingly increased
(Pakzaban et al., 1993; Olsson et al., 1995). Moreover, LGE-
restricted grafts showed more selective axonal growth towards
the GPe when compared to MGE grafts (Olsson et al., 1995).
It has therefore been argued that clinical grafts should be based
on a restricted LGE dissection in order to maximize the num-
ber of MSNs within the grafts and minimize contamination by
non-striatal cells (Brundin et al., 1996). However, although the
proportion of DARPP-32 neurons is increased in LGE grafts, not
only the total graft volume but also the volume of the patches
is greater in WGE grafts (Watts et al., 2000b). Moreover, there
is clear evidence of a more extensive functional recovery with
WGE than LGE grafting. Together, these observations suggest
that the reconstitution of all striatal cell types—both MSNs and
interneurons—within the graft tissue is important in optimizing
graft function (Dunnett, 2000). Interestingly, a recent experiment
in which LGE cells from a GDNF−/− or GDNF+/+ mouse were
grafted into the ventricles of WT mice has revealed that grafts
devoid of GDNF-expressing cells appeared smaller at 2 week
survival, and over time had less DARPP-32 and TH innervation
than grafts of wild-type tissue (Chermenina et al., 2014). In
the adult striatum GDNF is produced by the GABAergic and
cholinergic interneurons (Bizon et al., 1999; Hidalgo-Figueroa
et al., 2012), again suggesting that proper maturation of the
major populations of projection neurons within striatal grafts is
critically dependent upon factors only produced by inclusion of
striatal interneurons.
The use of human donor cells has produced slightly different
results to rat allograft experiments. At most only 30% of the
human LGE tissue grafted into the QA-lesioned rat striatum
consisted of P-zones (Grasbon-Frodl et al., 1996), although this
could be put down to species-specific rate of maturation (Tyson
and Anderson, 2013). However, a later experiment did show a
decrease in the number of apomorphine induced rotations com-
pared to post-lesion tests despite histology showing no definitive
P-zones (Sanberg et al., 1997) suggesting that the function of
the graft is not solely dependent on the specific striatal cellular
markers but depends on how well the graft connects with its
host.
Taken together, these observations suggest that if we are to
maximize functional impact we need to move beyond the resti-
tution of lost MSNs in a PSC-derived graft; we need to both
understand and pay attention to the full complement of striatal
and non-striatal cell types, along with their internal organiza-
tion, established within the grafted tissue and design graft com-
position accordingly. Despite the weight of evidence indicating
WGE grafts being favorable over the LGE, and increased P-zones
being preferred for functionality, current protocols directing
PSC to striatal fates largely focus on producing and testing an
MSN-pure, LGE-like phenotype, and with rare exceptions are
less concerned with the detailed cell morphology of the graft.
Upon histology, emphasis is placed upon molecular makers or
neurotransmitter makers indicative of an MSN, and of course
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whether there are any proliferating cells remaining to ensure no
possibility of tumor formation. No histological studies have yet
looked in depth at spine density or the numbers of interneurons,
and only one published protocol has assessed the presence of a
single MGE marker (Nkx2.1) in grafts (Ma et al., 2012). The
differentiation strategies typically adopted follow guidelines from
fetal development to apply a series of transcription factors and
other switches to progressively rostralise and dorsalise/ventralise
fates of differentiating cells converging on a particular stri-
atal population. This does not preclude the development of
interneurons as well as MSNs within the grafts as appropriate
to WGE (rather than pure LGE) targets. Rather, the selective
focus on the MSN target means that insufficient attention is
paid to the switch signals and markers of intermediates in cell
preparation and final neuronal fates of the differentiated cells
within PSC-derived grafts to allow us to determine the extent
to which complex striatal phenotypes are already being achieved
at present. Moreover, we need also to consider whether alterna-
tive differentiation protocols might yield more comprehensive
fate outcomes than the pure MSN composition of the grafts
per se.
CIRCUIT FORMATION
It is important that striatal grafts interact with the host envi-
ronment, i.e., that afferent and efferent connections are made.
Immunohistochemical staining can easily identify DA input to
the grafts (by TH staining of host-derived DA axons and ter-
minals), but for a more thorough analysis species-specific neu-
rofilament antibodies or optogenetic labels may need to be
used to allow more accurate visualization and quantification
of retrograde and anterograde fiber outgrowth (Wictorin et al.,
1990a, 1991). Typically, inputs and outputs from PFC striatal
grafts originate selectively from the P-zones (Wictorin et al.,
1989), i.e., the compartment comprising the subpopulation of
striatal-like neurons within the grafts. Moreover, combined Golgi
staining, immunohistochemical labeling, and anterograde and
retrograde pathway tracing at the electron microscopy level
has shown that host cortical inputs establish morphologically
appropriate symmetric synapses on the heads of the spines of
grafted MSN output neurons projecting to the GP, whereas
the host DA inputs make asymmetric synapses on the necks
of spines of the same neurons (Clarke et al., 1988; Clarke
and Dunnett, 1993), clearly demonstrating the key elements of
authentic circuit reconstruction. Similarly, both electrophysio-
logical (Rutherford et al., 1987; Siviy et al., 1993) and neu-
rochemical (Sirinathsinghji et al., 1988; Campbell et al., 1993)
studies indicate a clear relay of afferent and efferent information
between neurons within the grafts and host circuits. However,
how the striatal interneurons are contributing to grafts is still
unknown (or, at least, nowhere demonstrated directly) other
than by inference from our understanding of normal circuit
function.
Again, although several PSC-based protocols have checked
by whole-patch clamp analysis that the cells within the graft
express action potentials characteristic of neurons (Delli Carri
et al., 2013), only one has looked closely at projections within the
graft. Specifically Ma and colleagues showed that there was host
cortical and nigral inputs to the grafts and that there were efferent
projections afforded to the SN from the grafts (Ma et al., 2012).
It is likely that as protocols become more advanced, assessing
input and output connections and neurotransmitter release will
be routine as is the case for primary grafts.
FUNCTIONAL RECOVERY
Although striatal grafts can stain with striatal markers and show
connections to appropriate areas, whether these grafts have suc-
cessfully restored striatal circulatory and neurotransmitter levels
can only be determined by looking at functional recovery, the
ultimate goal of cell replacement therapy. There is a rich liter-
ature on studies demonstrating significant functional recovery
following PFC striatal transplantation on a broad range of motor
and cognitive tests in unilateral and bilateral striatal lesioned
rats (reviewed in Dunnett et al., 2000). These include recovery
in tests of motor function including locomotor activity, rotation
and rotational asymmetry, coordination and balance, and skilled
reaching and manipulation skills, and in the cognitive domain
including recovery in active and passive avoidance, active and
passive avoidance learning, spatial navigation and rule learning in
T and water mazes, and operant learning and delayed response
tasks. Importantly, these tests reveal clear recovery on tasks
dependent upon intact cortical fronto-striatal systems, clearly
implicating the restoration of circuit connectivity in functional
recovery (Dunnett et al., 2000). Most importantly, the use of
transfer of learning experiments in a lateralized operant habit
learning task has clearly indicated that the grafted tissues pro-
vide a necessary substrate for the formation of new learning
(rather than simply being necessary for the execution of the
response) (Brasted et al., 1999), and direct intracellular and
extracellular recording in striatal slices indicates the restoration
of characteristic synaptic plasticity at the reformed corticostri-
atal synapse between host circuits and graft cells necessary to
mediate such new learning (Mazzocchi-Jones et al., 2009). These
analyses indicate that it is not sufficient simply for a striatal
graft to replace lost neurons of the appropriate type and in
their appropriate location; rather, they must integrate into the
host circuitry to restore striatal modulation of cortical and tha-
lamic information in the flexible selection of action based on
experience and the history of reinforcement. Moreover, once the
substrate is restored, the grafted animal, and presumably also the
patient, requires to restore the lifetime of acquired motor skills
and habits lost to the disease process (Döbrössy and Dunnett,
2001).
THE CHALLENGES FOR PLURIPOTENT STEM CELL GRAFTS
Up to this stage in the commentary, we have established that
striatal grafts derived from implants of the developing striatal
primordium in the fetal ganglionic eminence can survive trans-
plantation, differentiate into appropriate populations and sub-
populations recapitulating the normal striatal phenotype, connect
and integrate with the host brain making appropriate synaptic
contacts to restore the basic components of the striatal circuitry,
and function according to neurochemical, electrophysiological
and behavioral criteria sufficient to alleviate a range of deficits
in both motor and cognitive domains associated with striatal
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neuronal cell loss and damage. Moreover, the observed recovery
is in processes such as S-R habit learning known to be dependent
upon restitution of functional cortical-striatal-pallidal circuits,
mediated by intracellular and synaptic plasticity involving LTP
and LTD, which are in turn dependent upon complex synap-
tic and intracellular signaling processes, integrating signals of
reward mediated by afferent dopaminergic and other brainstem
and thalamic inputs, and modulated by appropriate interaction
with interneurons within the local striatal networks. On the
one hand this sets the range of functional assessments that are
required to establish the functional viability and to characterize
the extent of functional recovery offered by an alternative cell
source, such as is provided by PSCs. On the other hand, given
the complexity of striatal organization, and the demonstrated
ability of authentic striatal primordium developing within PFC
grafts, it is to us implausible that relatively pure populations of
MSNs will have the capacity to either integrate or function to a
similar degree. This is not in any way to suggest that the MSNs are
not necessary or indeed fundamental. Rather, the known prin-
ciples of normal striatal organization and development demand
restoration of a functional complexity that is greater than initially
envisaged.
The existing protocols based on PSC transplantation, although
restricted in their scope, already provide good evidence of the
capacity of such grafts to provide a replacement of new neu-
rons that survive in the striatum, express multiple markers of
MSN differentiation, in particular GABAergic phenotypes and
DARPP32-positivity, limited outgrowth of graft neurites into the
host brain and re-afferentation by at least host dopamine fibers,
and partial recovery on some simple tests of motor asymmetry
(see Table 2). Anatomical and electrophysiological characteri-
zation of graft cells’ integration into host neuronal circuitries,
and recovery on a broader and more comprehensive profile of
functional tests has largely not yet been studied, but less func-
tional efficacy than is provided by existing PFC-derived grafts
would not be unexpected. This is unsurprising, based on the so
far selective targeting of one specific cell type, the MSN projec-
tion neuron; in the rare cases where a broader characterization
of interneuronal markers has been sought they have not been
identified. We can identify the need to progress the field at three
levels.
First, a broader characterization of PSC-based grafts is
required, in terms of cellular composition, molecular dif-
ferentiation of multiple striatal phenotypes, electrophysiolog-
ical and anatomical connectivity, and functional efficacy in
more complex motor and cognitive functions than the sim-
ple motor screening tests used to date. Such a broad profile
of characterization should become the norm rather than the
exception.
Second, the strategies for PSC differentiation to achieve a
cellular composition in the grafts that better reflects the full
composition of striatal interneurons, projection neurons and glia.
As we understand more about striatal development and can better
control distinct striatal fates, it is plausible to design additive
experiments to determine the combinations of cell types of which
the grafts are composed, and the components of circuit recon-
struction that are necessary and sufficient to achieve different
degrees and profiles of recovery in distinct motor, motivational,
cognitive and behavioral functional domains.
Thirdly, while PSC-derived grafts fall short of functional effi-
cacy achieved by PFC striatal tissues, the latter remains the “gold
standard”. However, PFC grafts are themselves not optimal; they
can vary markedly from case to case, the precise composition
of cell types, internal connections and rewiring and complete
functional recovery, never achieves the total repair that restores
the damaged system fully to normal. Especially with the much
greater degree of control we can potentially apply to PSC-derived
protocols, our goal should not simply be to provide a more
practical alternative that can match the present PFC standard, but
a new generation of cell therapy that can substantially supersede
our present still poor levels of competence.
The advantage that was offered by PFC -derived tissues in
the initial development of cell transplantation for HD lies in
the capacity of fetal neurons developing in situ for growth,
integration and function; that is what they have evolved to
do, and are features that are retained by the cells when trans-
planted into an adult damaged or diseased brain environment.
The challenge for the stem cell biologist is to understand that
process and design a more practical and effective replacement
that can still achieve the same complex fate, both in terms of
intrinsic capacity and of their ability to respond to the signals
provided by the host environment. The preceding considera-
tion of PFC-derived striatal grafts sets a high baseline of nec-
essary functional analysis for future generations of PSC-derived
cell therapy, not just as an empirical measure of functional
efficacy and recovery, but to determine and understand the
mechanisms of recovery and provide a rational foundation
for the design and implementation of an effective replacement
cells.
ACKNOWLEDGMENTS
The authors acknowledge the support of the UK Medical Research
Council and the European Union Framework 7 repair-HD (no.
602245) and Neurostemcell Repair (no. 602278) programmes in
funding our own studies in this area.
REFERENCES
Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy
of basal ganglia disorders. Trends Neurosci. 12, 366–375. doi: 10.1016/0166-
2236(89)90074-x
Arber, C., Precious, S. V., Cambray, S., Risner-Janiczek, J. R., Kelly, C. M.,
Heuer, A., et al. (in press). A novel strategy for generating transplantable
DARPP32-positive striatal projection neurons from human pluripotent stem
cells. Development.
Aubry, L., Bugi, A., Lefort, N., Rousseau, F., Peschanski, M., and Perrier, A. L.
(2008). Striatal progenitors derived from human ES cells mature into DARPP32
neurons in vitro and in quinolinic acid-lesioned rats. Proc. Natl. Acad. Sci. U S
A 105, 16707–16712. doi: 10.1073/pnas.0808488105
Bachoud-Lévi, A. C., Gaura, V., Brugières, P., Lefaucheur, J. P., Boissé, M. F.,
Maison, P., et al. (2006). Persistent benefit of foetal neural transplants in patients
with Huntington’s disease six years after surgery. Lancet Neurol. 5, 303–309.
doi: 10.1016/S1474-4422(06)70381-7
Bachoud-Lévi, A. C., Rémy, P., Nguyen, J. P., Brugières, P., Lefaucheur, J. P.,
Bourdet, C., et al. (2000). Motor and cognitive improvements in patients
with Huntington’s disease after neural transplantation. Lancet 356, 1975–1979.
doi: 10.1016/s0140-6736(00)03310-9
Barker, R. A., Mason, S. L., Harrower, T. P., Swain, R. A., Ho, A. K., Sahakian,
B. J., et al. (2013). The long term safety and efficacy of bilateral transplantation
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 398 | 11
Reddington et al. Striatal stem cell transplantation
of human fetal striatal tissue in patients with mild to moderate Huntington’s
disease. J. Neurol. Neurosurg. Psychiatry 84, 657–665. doi: 10.1136/jnnp-2012-
302441
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin,
J. B. (1986). Replication of the neurochemical characteristics of Huntington’s
disease by quinolinic acid. Nature 321, 168–171. doi: 10.1038/321168a0
Bizon, J. L., Lauterborn, J. C., and Gall, C. M. (1999). Subpopulations of
striatal interneurons can be distinguished on the basis of neurotrophic
factor expression. J. Comp. Neurol. 408, 283–298. doi: 10.1002/(sici)1096-
9861(19990531)408:2<283::aid-cne9>3.3.co;2-u
Brasted, P. J., Watts, C., Robbins, T. W., and Dunnett, S. B. (1999). Associative
plasticity in striatal transplants. Proc. Natl. Acad. Sci. U S A 96, 10524–10529.
doi: 10.1073/pnas.96.18.10524
Brundin, P., Fricker, R. A., and Nakao, N. (1996). Paucity of P-zones in striatal grafts
prohibit commencement of clinical trials in Huntington’s disease. Neuroscience
71, 895–897. doi: 10.1016/0306-4522(95)00162-x
Butler, H., and Juurlink, B. H. J. (1987). An Atlas for Staging Mammalian and Chick
Embryos. Boca Raton: CRC Press.
Campbell, K., and Björklund, A. (1995). Neurotransmitter-related gene expression
in intrastriatal striatal transplants. III. Regulation by host cortical and dopamin-
ergic afferents. Brain Res. Mol. Brain Res. 29, 263–272. doi: 10.1016/0169-
328x(94)00258-g
Campbell, K., Kalén, P., Wictorin, K., Lundberg, C., Mandel, R. J., and Björklund,
A. (1993). Characterization of GABA release from intrastriatal striatal trans-
plants: dependence on host-derived afferents. Neuroscience 53, 403–415. doi: 10.
1016/0306-4522(93)90204-s
Capetian, P., Knoth, R., Maciaczyk, J., Pantazis, G., Ditter, M., Bokla, L., et al.
(2009). Histological findings on fetal striatal grafts in a Huntington’s disease
patient early after transplantation. Neuroscience 160, 661–675. doi: 10.1016/j.
neuroscience.2009.02.035
Centonze, D., Gubellini, P., Bernardi, G., and Calabresi, P. (1999). Permissive role
of interneurons in corticostriatal synaptic plasticity. Brain Res. Brain Res. Rev.
31, 1–5. doi: 10.1016/s0165-0173(99)00018-1
Chen, G. J., Jeng, C. H., Lin, S. Z., Tsai, S. H., Wang, Y., and Chiang, Y. H. (2002).
Fetal striatal transplants restore electrophysiological sensitivity to dopamine in
the lesioned striatum of rats with experimental Huntington’s disease. J. Biomed.
Sci. 9, 303–310. doi: 10.1159/000065000
Chermenina, M., Schouten, P., Nevalainen, N., Johansson, F., Orädd, G., and
Strömberg, I. (2014). GDNF is important for striatal organization and mainte-
nance of dopamine neurons grown in the presence of the striatum. Neuroscience
270, 1–11. doi: 10.1016/j.neuroscience.2014.04.008
Cicchetti, F., Soulet, D., and Freeman, T. B. (2011). Neuronal degeneration in
striatal transplants and Huntington’s disease: potential mechanisms and clinical
implications. Brain 134, 641–652. doi: 10.1093/brain/awq328
Cisbani, G., Freeman, T. B., Soulet, D., Saint-Pierre, M., Gagnon, D., Parent, M.,
et al. (2013). Striatal allografts in patients with Huntington’s disease: impact of
diminished astrocytes and vascularization on graft viability. Brain 136(Pt. 2),
433–443. doi: 10.1093/brain/aws359
Clarke, D. J., and Dunnett, S. B. (1993). Synaptic relationships between cortical
and dopaminergic inputs and intrinsic GABAergic systems within intrastriatal
striatal grafts. J. Chem. Neuroanat. 6, 147–158. doi: 10.1016/0891-0618(93)
90024-x
Clarke, D. J., Dunnett, S. B., Isacson, O., Sirinathsinghji, D. J. S., and Björklund,
A. (1988). Striatal grafts in rats with unilateral neostriatal lesions. I. Ultrastruc-
tural evidence of afferent synaptic inputs from the host nigrostriatal pathway.
Neuroscience 24, 791–801. doi: 10.1016/0306-4522(88)90067-x
Clarke, D. J., Wictorin, K., Dunnett, S. B., and Bolam, J. P. (1994). “Internal com-
position of striatal grafts: light and electron microscopy,” in The Basal Ganglia
IV. New Ideas on Structure and Function, eds G. Percheron, J. S. McKenzie and J.
Féger (New York: Plenum Press), 189–196.
Deckel, A. W., Moran, T. H., Coyle, J. T., Sanberg, P. R., and Robinson, R. G. (1986).
Anatomical predictors of behavioral recovery following fetal striatal transplants.
Brain Res. 365, 249–258. doi: 10.1016/0006-8993(86)91636-7
Deckel, A. W., Moran, T. H., and Robinson, R. G. (1988a). Receptor characteristics
and recovery of function following kainic acid lesions and fetal transplants of
the striatum. 1. Cholinergic systems. Brain Res. 474, 27–38. doi: 10.1016/0006-
8993(88)90666-x
Deckel, A. W., Moran, T. H., and Robinson, R. G. (1988b). Receptor characteristics
and recovery of function following kainic acid lesions and fetal transplants of the
striatum. 2. Dopaminergic systems. Brain Res. 474, 39–47. doi: 10.1016/0006-
8993(88)90667-1
Delli Carri, A., Onorati, M., Lelos, M. J., Castiglioni, V., Faedo, A., Menon, R., et al.
(2013). Developmentally coordinated extrinsic signals drive human pluripotent
stem cell differentiation towards fully functional DARPP-32 positive medium-
sized spiny neurons. Development 140, 301–312. doi: 10.1242/dev.084608
DeLong, M. R. (1990). Primate models of movement disorders of basal ganglia
origin. Trends Neurosci. 13, 281–285. doi: 10.1016/0166-2236(90)90110-v
Dinsmore, J., Ratliff, J., Deacon, T., Pakzaban, P., Jacoby, D., Galpern, W., et al.
(1996). Embryonic stem cells differentiated in vitro as a novel source of cells
for transplantation. Cell Transplant. 5, 131–143. doi: 10.1016/0963-6897(95)
02040-3
Do, J., Kim, J. I., Bakes, J., Lee, K., and Kaang, B. K. (2012). Functional roles of
neurotransmitters and neuromodulators in the dorsal striatum. Learn. Mem. 20,
21–28. doi: 10.1101/lm.025015.111
Döbrössy, M. D., and Dunnett, S. B. (1998). Striatal grafts alleviate deficits in
response execution in a lateralised reaction time task. Brain Res. Bull. 47, 585–
593. doi: 10.1016/s0361-9230(98)00129-4
Döbrössy, M. D., and Dunnett, S. B. (2001). The influence of environment
and experience on neural grafts. Nat. Rev. Neurosci. 2, 871–879. doi: 10.
1038/35104055
Döbrössy, M. D., Klein, A., Janghra, N., Nikkhah, G., and Dunnett, S. B. (2011).
Validating the use of M4-BAC-GFP mice as tissue donors in cell replacement
therapies in a rodent model of Huntington’s disease. J. Neurosci. Methods 197,
6–13. doi: 10.1016/j.jneumeth.2011.01.015
Dunnett, S. B. (2000). “Functional analysis of fronto-striatal reconstruction by
striatal grafts,” in Neural Transplantation in Neurodegenerative Disease: Current
Status and New Directions, No.231, eds D. J. Chadwick and J. A. Goode (London:
Wiley), 21–42.
Dunnett, S. B., and Björklund, A. (2000). “Dissecting embryonic neural tissues for
transplantation,” in Neuromethods 36: Neural Transplantation Methods, ed S. B.
Dunnett, A. A. Boulton and G. B. Baker (Totowa, NJ: Humana Press), 3–25.
Dunnett, S. B., Carter, R. J., Watts, C., Torres, E. M., Mahal, A., Mangiarini, L., et
al. (1998). Striatal transplantation in a transgenic mouse model of Huntington’s
disease. Exp. Neurol. 154, 31–40. doi: 10.1006/exnr.1998.6926
Dunnett, S. B., Isacson, O., Sirinathsinghji, D. J. S., Clarke, D. J., and Björklund,
A. (1988). Striatal grafts in rats with unilateral neostriatal lesions. III. Recovery
from dopamine-dependent motor asymmetry and deficits in skilled paw reach-
ing. Neuroscience 24, 813–820. doi: 10.1016/0306-4522(88)90069-3
Dunnett, S. B., Nathwani, F., and Björklund, A. (2000). The integration and
function of striatal grafts. Prog. Brain Res. 127, 345–380. doi: 10.1016/s0079-
6123(00)27017-9
Dunnett, S. B., and Rosser, A. E. (2014). Challenges for taking primary and stem
cell therapies into clinical trials for neurodegenerative disease. Neurobiol. Dis.
61, 79–89. doi: 10.1016/j.nbd.2013.05.004
Dunnett, S. B., and White, A. (2006). Striatal grafts alleviate bilateral striatal lesion
deficits in operant delayed alternation in the rat. Experimental Neurology 199,
479–489. doi: 10.1016/j.expneurol.2006.01.013
Durieux, P. F., Schiffmann, S. N., and de Kerchove, d. E. A. (2011). Targeting neu-
ronal populations of the striatum. Front. Neuroanat. 5:40. doi: 10.3389/fnana.
2011.00040
El-Akabawy, G., Medina, L. M., Jeffries, A., Price, J., and Modo, M. (2011).
Purmorphamine increases DARPP-32 differentiation in human striatal neural
stem cells through the Hedgehog pathway. Stem Cells Dev. 20, 1873–1887.
doi: 10.1089/scd.2010.0282
El-Akabawy, G., Rattray, I., Johansson, S. M., Gale, R., Bates, G., and Modo, M.
(2012). Implantation of undifferentiated and predifferentiated human neural
stem cells in the R6/2 transgenic mouse model of Huntington’s disease. BMC
Neurosci. 13:97. doi: 10.1186/1471-2202-13-97
Emerich, D. F., Zubrycki, E. M., Shipley, M. T., Norman, A. B., and Sanberg, P. R.
(1991). Female rats are more sensitive to the locomotor alterations following
quinolinic acid-induced striatal lesions: effects of striatal transplants. Exp.
Neurol. 111, 369–378. doi: 10.1016/0014-4886(91)90105-l
Evans, A. E., Kelly, C. M., Precious, S. V., and Rosser, A. E. (2012). Molecular
regulation of striatal development: a review. Anat. Res. Int. 2012:106529. doi: 10.
1155/2012/106529
Feng, Q., Ma, Y., Mu, S., Wu, J., Chen, S., Ouyang, L., et al. (2014). Specific reactions
of different striatal neuron types in morphology induced by quinolinic acid in
rats. PLoS One 9:e91512. doi: 10.1371/journal.pone.0091512
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 398 | 12
Reddington et al. Striatal stem cell transplantation
Freeman, T. B., Cicchetti, F., Bachoud-Lévi, A. C., and Dunnett, S. B. (2011).
Technical factors that influence neural transplant safety in Huntington’s disease.
Exp. Neurol. 227, 1–9. doi: 10.1016/j.expneurol.2010.08.031
Freeman, T. B., Cicchetti, F., Hauser, R. A., Deacon, T. W., Li, X. J., Hersch, S. M.,
et al. (2000). Transplanted fetal striatum in Huntington’s disease: phenotypic
development and lack of pathology. Proc. Natl. Acad. Sci. U S A 97, 13877–13882.
doi: 10.1073/pnas.97.25.13877
Freeman, T. B., Sanberg, P. R., and Isacson, O. (1995). Development of the human
striatum: implications for fetal striatal transplantation in the treatment of
Huntington’s disease. Cell Transplant. 4, 539–545. doi: 10.1016/0963-6897(95)
00013-n
Fricker, R. A., Torres, E. M., Lombroso, P. J., and Dunnett, S. B. (1994). STEP, a
novel striatal marker to distinguish patch/non-patch organisation of embryonic
striatal transplants in the ibotenic acid lesioned neostriatum of the rat. Neurore-
port 5, 2638–2640.
Fujiyama, F., Sohn, J., Nakano, T., Furuta, T., Nakamura, K. C., Matsuda, W., et
al. (2011). Exclusive and common targets of neostriatofugal projections of rat
striosome neurons: a single neuron-tracing study using a viral vector. Eur. J.
Neurosci. 33, 668–677. doi: 10.1111/j.1460-9568.2010.07564.x
Gerfen, C. R. (1992). The neostriatal mosaic - multiple levels of compartmental
organization in the basal ganglia. Annu. Rev. Neurosci. 15, 285–320. doi: 10.
1146/annurev.neuro.15.1.285
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma,
F. J., et al. (1990). D1 and D2 dopamine receptor regulated gene expression
of striatonigral and striatopallidal neurons. Science 250, 1429–1432. doi: 10.
1126/science.2147780
Gerfen, C. R., and Young, W. S. (1988). Distribution of striatonigral and striatopal-
lidal peptidergic neurons in both patch and matrix compartments: an in situ
hybridization histochemistry and fluorescent retrograde tracing study. Brain
Res. 460, 161–167. doi: 10.1016/0006-8993(88)91217-6
Giordano, M., Ford, L. M., Shipley, M. T., and Sanberg, P. R. (1990). Neural grafts
and pharmacological intervention in a model of Huntington’s disease. Brain Res.
Bull. 25, 453–465. doi: 10.1016/0361-9230(90)90238-u
Giordano, M., Salado-Castillo, R., Sánchez-Alavez, M., and Prado-Alcalá, R. A.
(1998). Striatal transplants prevent AF64A-induced retention deficits. Life Sci.
63, 1953–1961. doi: 10.1016/s0024-3205(98)00473-1
Grasbon-Frodl, E. M., and Brundin, P. (1997). Mesencephalic neuron death
induced by congeners of nitrogen monoxide is prevented by the lazaroid U-
83836E. Exp. Brain Res. 113, 138–143. doi: 10.1007/bf02454149
Grasbon-Frodl, E. M., Nakao, N., Lindvall, O., and Brundin, P. (1996). Phenotypic
development of the human embryonic striatal primordium: a study of cultured
and grafted neurons from the lateral and medial ganglionic eminence. Neuro-
science 73, 171–183. doi: 10.1016/0306-4522(96)00008-5
Grasbon-Frodl, E. M., Nakao, N., Lindvall, O., and Brundin, P. (1997). Devel-
opmental features of human striatal tissue transplanted in a rat model of
Huntington’s disease. Neurobiol. Dis. 3, 299–311. doi: 10.1006/nbdi.1996.
0124
Graybiel, A. M., Liu, F. C., and Dunnett, S. B. (1989). Intrastriatal grafts derived
from fetal striatal primordia. 1. Phenotypy and modular organization. J. Neu-
rosci. 9, 3250–3271.
Helm, G. A., Palmer, P. E., and Bennett, J. P. (1990). Fetal neostriatal transplants in
the rat: a light and electron microscopic Golgi study. Neuroscience 37, 735–756.
doi: 10.1016/0306-4522(90)90104-c
Helm, G. A., Palmer, P. E., and Bennett, J. P. (1992). Choline acetyltransferase-
and substance P-like immunoreactive elements in fetal striatal grafts in the rat:
a correlated light and electron microscopic study. Neuroscience 47, 621–639.
doi: 10.1016/0306-4522(92)90171-w
Hidalgo-Figueroa, M., Bonilla, S., Gutiérrez, F., Pascual, A., and López-Barneo, J.
(2012). GDNF is predominantly expressed in the PV+ neostriatal interneuronal
ensemble in normal mouse and after injury of the nigrostriatal pathway. J.
Neurosci. 32, 864–872. doi: 10.1523/jneurosci.2693-11.2012
Hussain, N., Flumerfelt, B. A., and Rajakumar, N. (2004). Glutamatergic regulation
of long-term grafts of fetal lateral ganglionic eminence in a rat model of
Huntington’s disease. Neurobiol. Dis. 15, 648–653. doi: 10.1016/j.nbd.2003.
12.005
Isacson, O., Brundin, P., Gage, F. H., and Björklund, A. (1985). Neural grafting in
a rat model of Huntington’s disease: progressive neurochemical changes after
neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 16, 799–
817. doi: 10.1016/0306-4522(85)90095-8
Isacson, O., Brundin, P., Kelly, P. A. T., Gage, F. H., and Björklund, A. (1984).
Functional neuronal replacement by grafted striatal neurons in the ibotenic acid
lesioned rat striatum. Nature 311, 458–460. doi: 10.1038/311458a0
Isacson, O., Dawbarn, D., Brundin, P., Gage, F. H., Emson, P. C., and Björklund, A.
(1987). Neural grafting in a rat model of Huntington’s disease: striosomal-like
organization of striatal grafts as revealed by acetylcholinesterase histochemistry,
immunocytochemistry and receptor autoradiography. Neuroscience 22, 481–
497. doi: 10.1016/0306-4522(87)90348-4
Jain, M., Armstrong, R. J. E., Barker, R. A., and Rosser, A. E. (2001). Cellular and
molecular aspects of striatal development. Brain Res. Bull. 55, 533–540. doi: 10.
1016/s0361-9230(01)00555-x
Jimhénez-Castellanos, J., and Graybiel, A. M. (1989). Compartmental origins
of striatal efferent projections in the cat. Neuroscience 32, 297–321. doi: 10.
1016/0306-4522(89)90080-8
Joannides, A. J., FioreHériché, C., Battersby, A. A., AthaudaArachchi, P., Bouhon,
I. A., Williams, L., et al. (2007a). A scaleable and defined system for generating
neural stem cells from human embryonic stem cells. Stem Cells 25, 731–737.
doi: 10.1634/stemcells.2006-0562
Joannides, A. J., Webber, D. J., Raineteau, O., Kelly, C., Irvine, K. A., Watts, C.,
et al. (2007b). Environmental signals regulate lineage choice and temporal
maturation of neural stem cells from human embryonic stem cells. Brain 130,
1263–1275. doi: 10.1093/brain/awm070
Kallur, T., Darsalia, V., Lindvall, O., and Kokaia, Z. (2006). Human fetal cortical
and striatal neural stem cells generate region-specific neurons in vitro and
differentiate extensively to neurons after intrastriatal transplantation in neonatal
rats. J. Neurosci. Res. 84, 1630–1644. doi: 10.1002/jnr.21066
Keene, C. D., Sonnen, J. A., Swanson, P. D., Kopyov, O., Leverenz, J. B., Bird, T. D.,
et al. (2007). Neural transplantation in Huntington disease: long-term grafts
in two patients. Neurology 68, 2093–2098. doi: 10.1212/01.wnl.0000264504.
14301.f5
Kendall, A. L., Rayment, F. D., Torres, E. M., Baker, H. F., Ridley, R. M., and
Dunnett, S. B. (1998). Functional integration of striatal allografts in a pri-
mate model of Huntington’s disease. Nat. Med. 4, 727–729. doi: 10.1038/
nm0698-727
Klein, A., Lane, E. L., and Dunnett, S. B. (2013). Brain repair in a rat model
of Huntington’s disease: new insights into motor impairment and restora-
tion of forelimb movement patterns. Cell Transplant. 22, 1735–1751. doi: 10.
3727/096368912X657918
Labandeira-García, J. L., Wictorin, K., Cunningham, E. T., and Björklund, A.
(1991). Development of intrastriatal striatal grafts and their afferent inner-
vation from the host. Neuroscience 42, 407–426. doi: 10.1016/0306-4522(91)
90385-2
Lee, S. T., Chu, K., Jung, K. H., Im, W. S., Park, J. E., Lim, H. C., et al. (2009). Slowed
progression in models of Huntington disease by adipose stem cell transplant..
Ann. Neurol. 66, 671–681. doi: 10.1002/ana.21788
Lee, S. T., Park, J. E., Lee, K., Kang, L., Chu, K., Kim, S. U., et al. (2006). Noninvasive
method of immortalized neural stem-like cell transplant. in an experimental
model of Huntington’s disease. J. Neurosci. Methods 152, 250–254. doi: 10.1016/j.
jneumeth.2005.09.013
Liu, F. C., Graybiel, A. M., Dunnett, S. B., and Baughman, R. W. (1990). Intrastriatal
grafts derived from fetal striatal primordia. 2. Reconstitution of cholinergic and
dopaminergic systems. J. Comp. Neurol. 295, 1–14. doi: 10.1002/cne.902950102
Lu, S. Y., and Norman, A. B. (1993). Neurotransmitter receptors in fetal tissue
transplants: expression and functional significance. J. Neural Transplant. Plast.
4, 215–226. doi: 10.1155/np.1993.215
Ma, L., Hu, B., Liu, Y., Vermilyea, S. C., Liu, H., Gao, L., et al. (2012). Human
embryonic stem cell-derived GABA neurons correct locomotion deficits in
quinolinic acid-lesioned mice. Cell Stem Cell 10, 455–464. doi: 10.1016/j.stem.
2012.01.021
Mayer, E., Brown, V. J., Dunnett, S. B., and Robbins, T. W. (1992). Striatal graft-
associated recovery of a lesion-induced performance deficit in the rat requires
learning to use the transplant. Eur. J. Neurosci. 4, 119–126. doi: 10.1111/j.1460-
9568.1992.tb00858.x
Mazzocchi-Jones, D., Döbrössy, M. D., and Dunnett, S. B. (2009). Synaptic plastic-
ity in striatal grafts. Eur. J. Neurosci. 30, 2134–2142. doi: 10.1007/0-387-28066-
9_29
Mazzocchi-Jones, D., Döbrössy, M. D., and Dunnett, S. B. (2011). Environmental
enrichment facilitates long-term potentiation in embryonic striatal grafts. Neu-
rorehabil. Neural Repair. 25, 548–557. doi: 10.1177/1545968311402090
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 398 | 13
Reddington et al. Striatal stem cell transplantation
Montoya, C. P., Astell, S., and Dunnett, S. B. (1990). Effects of nigral and striatal
grafts on skilled forelimb use in the rat. Prog. Brain Res. 82, 459–466. doi: 10.
1016/s0079-6123(08)62634-5
Morris, B. J., Wisden, W., Dunnett, S. B., and Sirinathsinghji, D. J. S. (1989).
Cellular localization of somatostatin mRNA and neuropeptide Y mRNA in
fetal striatal tissue grafts. Neurosci. Lett. 103, 121–126. doi: 10.1016/0304-
3940(89)90562-4
Morton, A. J., Lagan, M., Skepper, J. N., and Dunnett, S. B. (2000). Progressive
formation of inclusions in the brains of mice transgenic for the human Hunting-
ton’s disease mutation parallels neurological decline. J. Neurocytol. 29, 679–702.
doi: 10.1023/A:1010887421592
Nakao, N., Nakai, K., and Itakura, T. (2000). Fetal striatal transplants reinstate
the electrophysiological response of pallidal neurons to systemic apomorphine
challenge in rats with excitotoxic striatal lesions. Eur. J. Neurosci. 12, 3426–3432.
doi: 10.1046/j.1460-9568.2000.00212.x
Nakao, N., Odin, P., and Brundin, P. (1994). Selective sub-dissection of the striatal
primordium for cultures affects the yield of DARPP-32-containing neurones.
Neuroreport 5, 1081–1084. doi: 10.1097/00001756-199405000-00015
Nakao, N., Ogura, M., Nakai, K., and Itakura, T. (1999). Embryonic striatal
grafts restore neuronal activity of the globus pallidus in a rodent model of
Huntington’s disease. Neuroscience 88, 469–477. doi: 10.1016/s0306-4522(98)
00197-3
Nasonkin, I., Mahairaki, V., Xu, L., Hatfield, G., Cummings, B. J., Eberhart, C., et al.
(2009). Long-term, stable differentiation of human embryonic stem cell-derived
neural precursors grafted into the adult mammalian neostriatum. Stem Cells 27,
2414–2426. doi: 10.1002/stem.177
Nicoleau, C., Varela, C., Bonnefond, C., Maury, Y., Bugi, A., Aubry, L., et al. (2013).
Embryonic stem cells neural differentiation qualifies the role of Wnt/beta-
Catenin signals in human telencephalic specification and regionalization. Stem
Cells 31, 1763–1774. doi: 10.1002/stem.1462
Norman, A. B., Calderon, S. F., Giordano, M., and Sanberg, P. R. (1988). Striatal
tissue transplants attenuate apomorphine induced rotational behavior in rats
with unilateral kainic acid lesions. Neuropharmacology 27, 333–336. doi: 10.
1016/0028-3908(88)90053-6
Norman, A. B., Giordano, M., and Sanberg, P. R. (1989). Fetal striatal tissue grafts
into excitotoxin-lesioned striatum: pharmacological and behavioral aspects.
Pharmacol. Biochem. Behav. 34, 139–147. doi: 10.1016/0091-3057(89)90365-1
Olsson, M., Campbell, K., Wictorin, K., and Björklund, A. (1995). Projection
neurons in fetal striatal transplants are predominantly derived from the lat-
eral ganglionic eminence. Neuroscience 69, 1169–1182. doi: 10.1016/0306-
4522(95)00325-d
O’Rahilly, R., and Müller, F. (1987). Developmental Stages in Human Embryos.
Washington: Carnegie Institute.
Pakzaban, P., Deacon, T. W., Burns, L. H., and Isacson, O. (1993). Increased
proportion of acetylcholinesterase-rich zones and improved morphological
integration in host striatum of fetal grafts derived from the lateral but not the
medial ganglionic eminence. Exp. Brain Res. 97, 13–22. doi: 10.1007/bf00228813
Palfi, S., Condé, F., Riche, D., Brouillet, E., Dautry, C., Mittoux, V., et al. (1998).
Fetal striatal allografts reverse cognitive deficits in a primate model of Hunting-
ton’s disease. Nat. Med. 4, 963–966. doi: 10.1038/nm0898-963
Petit, A., Quenneville, N., Vallée, A., Pierret, P., and Doucet, G. (2002). Differences
in host serotonin innervation of intrastriatal grafts are not determined by a
glial scar or chondroitin sulfate proteoglycans. Exp. Neurol. 177, 61–74. doi: 10.
1006/exnr.2002.7954
Pierret, P., Vallée, A., Bosler, O., Dorais, M., Moukhles, H., Abbaszadeh, R., et al.
(1998). Serotonin axons of the neostriatum show a higher affinity for striatal
than for ventral mesencephalic transplants: a quantitative study in adult and
immature recipient rats. Exp. Neurol. 152, 101–115. doi: 10.1006/exnr.1998.
6823
Piña, A. L., Ormsby, C. E., and Bermúdez-Rattoni, F. (1994a). Differential recov-
ery of inhibitory avoidance learning by striatal, cortical and mesencephalic
fetal grafts. Behav. Neural Biol. 61, 196–201. doi: 10.1016/s0163-1047(05)
80076-7
Piña, A. L., Ormsby, C. E., Miranda, M. I., Jiménez, N., Tapia, R., and Bermúdez-
Rattoni, F. (1994b). Graft-induced recovery of inhibitory avoidance condition-
ing in striatal lesioned rats is related to choline acetyltransferase activity. J.
Neural Transplant. Plast. 5, 11–16. doi: 10.1155/np.1994.11
Pritzel, M., Isacson, O., Brundin, P., Wiklund, L., and Björklund, A. (1986).
Afferent and efferent connections of striatal grafts implanted into the ibotenic
acid lesioned neostriatum in adult rats. Exp. Brain Res. 65, 112–126. doi: 10.
1007/bf00243834
Pundt, L. L., Kondoh, T., Conrad, J. A., and Low, W. C. (1996). Transplantation of
human striatal tissue into a rodent model of Huntington’s disease: phenotypic
expression of transplanted neurons and host-to-graft innervation. Brain Res.
Bull. 39, 23–32. doi: 10.1016/0361-9230(95)02029-2
Reading, P. J., and Dunnett, S. B. (1995). Embryonic striatal grafts ameliorate the
disinhibitory effects of ventral striatal lesions. Exp. Brain Res. 105, 76–86. doi: 10.
1007/bf00242184
Reiner, A., Albin, R. L., Anderson, K. D., D’Amato, C. J., Penney, J. B., and Young,
A. B. (1988). Differential loss of striatal projection neurons in Huntington
disease. Proc. Natl. Acad. Sci. U S A 85, 5733–5737. doi: 10.1073/pnas.85.15.
5733
Roberton, V. H., Evans, A. E., Harrison, D. J., Precious, S. V., Dunnett, S. B.,
Kelly, C. M., et al. (2013). Is the adult mouse striatum a hostile host for neural
transplant survival? Neuroreport 24, 1010–1015. doi: 10.1097/wnr.0000000000
000066
Roberts, R. C., and DiFiglia, M. (1988). Localization of immunoreactive GABA
and enkephalin and NADPH- diaphorase-positive neurons in fetal striatal grafts
in the quinolinic acid-lesioned rat neostriatum. J. Comp. Neurol. 274, 406–421.
doi: 10.1002/cne.902740309
Rosser, A. E., Barker, R. A., Guillard, J., Harrower, T., Watts, C., Pickard, J., et al.
(2002). Unilateral transplantation of human primary fetal tissue in four patients
with Huntington’s disease: NEST-UK safety report (ISRCTN no 36485475). J.
Neurol. Neurosurg. Psychiatry 73, 678–685. doi: 10.1136/jnnp.73.6.678
Rutherford, A., Garcia-Muñoz, M., Dunnett, S. B., and Arbuthnott, G. W. (1987).
Electrophysiological demonstration of host cortical inputs to striatal grafts.
Neurosci. Lett. 83, 275–281. doi: 10.1016/0304-3940(87)90099-1
Sanberg, P. R., Borlongan, C. V., Koutouzis, T. K., Norgren, R. B., Cahill, D. W., and
Freeman, T. B. (1997). Human fetal striatal transplantation in an excitotoxic
lesioned Huntington’s disease model: a preliminary study. Ann. N Y Acad. Sci.
831, 452–460. doi: 10.1111/j.1749-6632.1997.tb52217.x
Saporta, S., Willing, A. E., Zigova, T., Daadi, M. M., and Sanberg, P. R. (2001).
Comparison of calcium-binding proteins expressed in cultured hNT neurons
and hNT neurons transplanted into the rat striatum. Exp. Neurol. 167, 252–259.
doi: 10.1006/exnr.2000.7550
Schmidt, R. H., Björklund, A., and Stenevi, U. (1981). Intracerebral grafting of
dissociated CNS tissue suspensions: a new approach for neuronal transplanta-
tion to deep brain sites. Brain Res. 218, 347–356. doi: 10.1016/0006-8993(81)
91313-5
Sirinathsinghji, D. J. S., Dunnett, S. B., Isacson, O., Clarke, D. J., Kendrick, K., and
Björklund, A. (1988). Striatal grafts in rats with unilateral neostriatal lesions.
II. In vivo monitoring of GABA release in globus pallidus and substantia nigra.
Neuroscience 24, 803–811. doi: 10.1016/0306-4522(88)90068-1
Sirinathsinghji, D. J. S., Heavens, R. P., Torres, E. M., and Dunnett, S. B. (1993).
Cholecystokinin-dependent regulation of host dopamine inputs to striatal
grafts. Neuroscience 53, 651–663. doi: 10.1016/0306-4522(93)90613-k
Sirinathsinghji, D. J. S., Morris, B. J., Wisden, W., Northrop, A., Hunt, S. P., and
Dunnett, S. B. (1990). Gene expression in striatal grafts. 1. Cellular localization
of neurotransmitter mRNAs. Neuroscience 34, 675–686. doi: 10.1016/0306-
4522(90)90174-3
Siviy, S. M., Walsh, J. P., Radisavljevic, Z., Cohen, R. W., Buchwald, N. A., and
Levine, M. S. (1993). Evidence for enhanced synaptic excitation in trans-
planted neostriatal neurons. Exp. Neurol. 123, 222–234. doi: 10.1006/exnr.1993.
1155
Song, J., Lee, S. T., Kang, W., Park, J. E., Chu, K., Lee, S. E., et al. (2007).
Human embryonic stem cell-derived neural precursor transplants attenuate
apomorphine-induced rotational behavior in rats with unilateral quinolinic acid
lesions. Neurosci. Lett. 423, 58–61. doi: 10.1016/j.neulet.2007.05.066
Surmeier, D. J., Xu, Z. C., Wilson, C. J., Stefani, A., and Kitai, S. T. (1992). Grafted
neostriatal neurons express a late-developing transient potassium current. Neu-
roscience 48, 849–856. doi: 10.1016/0306-4522(92)90273-5
Tepper, J. M., Tecuapetla, F., Koós, T., and Ibáñez-Sandoval, O. (2010). Heterogene-
ity and diversity of striatal GABAergic interneurons. Front. Neuroanat. 4:150.
doi: 10.3389/fnana.2010.00150
Tyson, J. A., and Anderson, S. A. (2013). The protracted maturation of human ESC-
derived interneurons. Cell Cycle 12, 3129–3130. doi: 10.4161/cc.26351
Vazey, E. M., Dottori, M., Jamshidi, P., Tomas, D., Pera, M. F., Horne, M., et
al. (2010). Comparison of transplant efficiency between spontaneously-derived
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 398 | 14
Reddington et al. Striatal stem cell transplantation
and noggin-primed human embryonic stem cell neural precursors in the quino-
linic acid rat model of Huntington’s disease. Cell Transplant. 19, 1055–1062.
doi: 10.3727/096368910x494632
Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., and Richard-
son, E. P. Jr. (1985). Neuropathologic classification of Huntington’s disease.
J. Neuropathol. Exp. Neurol. 44, 559–577. doi: 10.1097/00005072-198511000-
00003
Walsh, J. P., Zhou, F. C., Hull, C. D., Fisher, R. S., Levine, M. S., and Buchwald, N. A.
(1988). Physiological and morphological characterization of striatal neurons
transplanted into the striatum of adult rats. Synapse 2, 37–44. doi: 10.1002/syn.
890020107
Watts, C., Brasted, P. J., and Dunnett, S. B. (2000a). The morphology, integration
and functional efficacy of striatal grafts differs between cell suspensions and
tissue pieces. Cell Transplant. 9, 395–407.
Watts, C., Brasted, P. J., Eagle, D. M., and Dunnett, S. B. (2000b). Embryonic
donor age and dissection influence striatal graft development and functional
integration in a rodent model of Huntington’s disease. Exp. Neurol. 163, 85–97.
doi: 10.1006/exnr.1999.7341
Watts, C., McNamara, I., and Dunnett, S. B. (2000c). Volume and differentiation
of striatal grafts in rats: relationship to the number of cells implanted. Cell
Transplant. 9, 65–72.
Wictorin, K., and Björklund, A. (1989). Connectivity of striatal grafts implanted
into the ibotenic acid- lesioned striatum. 2. Cortical afferents. Neuroscience 30,
297–311. doi: 10.1016/0306-4522(89)90255-8
Wictorin, K., Brundin, P., Gustavii, B., Lindvall, O., and Björklund, A. (1990a).
Reformation of long axon pathways in adult rat central nervous system by
human forebrain neuroblasts. Nature 347, 556–558. doi: 10.1038/347556a0
Wictorin, K., Clarke, D. J., Bolam, J. P., and Björklund, A. (1990b). Fetal striatal
neurons grafted into the ibotenate lesioned adult striatum: efferent projections
and synaptic contacts in the host globus pallidus. Neuroscience 37, 301–315.
doi: 10.1016/0306-4522(90)90401-o
Wictorin, K., Isacson, O., Fischer, W., Nothias, F., Peschanski, M., and Björklund, A.
(1988). Connectivity of striatal grafts implanted into the ibotenic acid-lesioned
striatum. 1. Subcortical afferents. Neuroscience 27, 547–562. doi: 10.1016/0306-
4522(88)90288-6
Wictorin, K., Lagenaur, C. F., Lund, R. D., and Björklund, A. (1991). Effer-
ent projections to the host brain from intrastriatal striatal mouse-to-rat
grafts: time course and tissue-type specificity as revealed by a mouse specific
neuronal marker. Eur. J. Neurosci. 3, 86–101. doi: 10.1111/j.1460-9568.1991.
tb00814.x
Wictorin, K., Ouimet, C. C., and Björklund, A. (1989). Intrinsic organiza-
tion and connectivity of intrastriatal striatal transplants in rats as revealed
by DARPP-32 immunohistochemistry: specificity of connections with the
lesioned host brain. Eur. J. Neurosci. 1, 690–701. doi: 10.1111/j.1460-9568.1989.
tb00375.x
Xu, Z. C., Wilson, C. J., and Emson, P. C. (1991). Synaptic potentials evoked in
spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J.
Neurophysiol. 65, 477–493.
Zhu, M., Shu, K., Wang, H., Li, X., Xiao, Q., Chan, W., et al. (2013).
Microtransplantation of whole ganglionic eminence cells ameliorates motor
deficit, enlarges the volume of grafts and prolongs survival in a rat model
of Huntington’s disease. J. Neurosci. Res. 91, 1563–1571. doi: 10.1002/jnr.
23282
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 23 September 2014; accepted: 05 November 2014; published online: 02
December 2014.
Citation: Reddington AE, Rosser AE and Dunnett SB (2014) Differentiation of
pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be
sufficient. Front. Cell. Neurosci. 8:398. doi: 10.3389/fncel.2014.00398
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Reddington, Rosser and Dunnett. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution and reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 398 | 15
